Open Label Trial of a Single Day Induction onto Buprenorphine Extended-Release Injection for Users of Heroin and Fentanyl
| Autor: | Frances R. Levin, John J. Mariani, Amy L. Mahony, Samuel C Podell, Nasir H. Naqvi, Daniel J. Brooks, Sean X. Luo, Christina A. Brezing |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Adult
Narcotic Antagonists Medicine (miscellaneous) Article Fentanyl Heroin medicine Humans business.industry Opioid overdose Opioid use disorder medicine.disease Opioid-Related Disorders United States Buprenorphine Clinical trial Analgesics Opioid Psychiatry and Mental health Clinical Psychology Anesthesia Open label Extended release business medicine.drug |
| Zdroj: | Am J Addict |
| Popis: | Background and objectives Fentanyl and other highly potent synthetic opioids are the leading cause of opioid overdose deaths in the United States. Methods This study was an open-label, uncontrolled 12-week outpatient clinical trial to test the feasibility of a single-day induction onto extended-release buprenorphine (BXR) injection treatment for five adults (N = 5) with opioid use disorder using heroin-containing fentanyl. Participants were planned to receive three monthly BXR injections (300, 300, and 100 mg). Results After receiving 24 mg sublingual buprenorphine (SL-BUP), all five participants received the BXR 300 mg injection on the first day of induction. All five participants were retained for the full 3-month study period postinduction and received all three scheduled BXR injections. Discussion and conclusion This study provides preliminary evidence supporting the feasibility of inducting users of heroin-containing fentanyl onto BXR 300 mg in a single day. Scientific significance The ability to administer a long-acting injection of BXR that assures therapeutic serum levels for a month on the first day of treatment contact is a promising development for the treatment of OUD. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|